A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high‐risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group

Children with high‐risk medulloblastoma historically have had a poor prognosis. The Children's Oncology Group completed a Phase II study using oral etoposide given with radiotherapy followed by intensive chemotherapy.

[1]  G. Perilongo,et al.  Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. , 2014, Neuro-oncology.

[2]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[3]  B. Geoerger,et al.  Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. , 2013, Neuro-oncology.

[4]  T. Zhou,et al.  High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Zhou,et al.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. , 2013, Neuro-oncology.

[6]  T. Björk-Eriksson,et al.  Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[8]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[9]  M. Mehta,et al.  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[11]  M. Prados,et al.  A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). , 2009, International journal of radiation oncology, biology, physics.

[12]  E. Garrett-Mayer,et al.  High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas , 2009, Journal of Neuro-Oncology.

[13]  A. Tubiana,et al.  Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. , 2006, European journal of cancer.

[14]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[15]  L. Rorke,et al.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Chamberlain,et al.  Chronic oral VP-16 for recurrent medulloblastoma. , 1997, Pediatric neurology.

[17]  P. Phillips,et al.  Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. , 1997, Medical and pediatric oncology.

[18]  C. R. Pinkerton,et al.  Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). , 1997, European journal of cancer.

[19]  S. Lowis,et al.  Phase II study of 21 day schedule oral etoposide in children , 1997 .

[20]  H. Friedman,et al.  Response of recurrent medulloblastoma to low-dose oral etoposide. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Harisiadis,et al.  Medulloblastoma in children: a correlation between staging and results of treatment. , 1977, International journal of radiation oncology, biology, physics.